MIDTERM PRIMARY VOTING RESULTS

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

163.75 +6.37 (+4.05%)
Streaming Delayed Price Updated: 2:34 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗
 
Via Benzinga
News headline image
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
News headline image
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing ↗
 
Via Benzinga
News headline image
Analyst Ratings for Guardant Health ↗
Within the last quarter, Guardant Health (NASDAQ:GH) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Guardant Health Q2 Earnings ↗
Guardant Health (NASDAQ:GH) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:03 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report ↗
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
News headline image
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
From Guardant Health, Inc.
Via Business Wire
News headline image
Lululemon, Smartsheet, Okta, And Other Big Gainers From Friday ↗
U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Friday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
No More Free COVID-19 At-Home Tests, Federal Government Says ↗
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
News headline image
Why Micro Focus International Is Trading Higher By Around 94%; Here Are 28 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Guardant Health's Return On Capital Employed Insights ↗
Benzinga Pro data, Guardant Health (NASDAQ:GH) reported Q2 sales of $109.14 million. Earnings fell to a loss of $229.43 million, resulting in a 86.18% decrease from last quarter. 
Via Benzinga
News headline image
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
From Guardant Health, Inc.
Via Business Wire
News headline image
Recap Of Friday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation ↗
 
Via Benzinga
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
News headline image
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
Uber Dumped By Large Shareholder As Billionaire's 'Vision' Suffers Investment Struggles ↗
After reporting one of its largest losses ever, SoftBank Group Corp (OTC: SFTBY) has turned to alternative methods to regain lost capital. 
Via Benzinga
News headline image
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Reports Second Quarter 2022 Financial Results
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
From Guardant Health, Inc.
Via Business Wire
News headline image
5 Top Stocks Cathie Wood Bought This Week ↗
Despite a 50% YTD drawdown in ARKK, Cathie Wood has continued her purchases of high growth companies, such as TDOC and BILL stocks. 
Via InvestorPlace
News headline image
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
From Guardant Health, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article